ArticleHealth science reports2026
Spectrum of Pathogens and Their Resistance Profiles in Sputum and Pus Samples: A Retrospective Study From an Eastern Hospital of Nepal.
Article in Health science reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aims: Respiratory and soft tissue infections remain major public health challenges both globally and in Nepal, increasingly complicated by rising antimicrobial resistance (AMR). The emergence of multidrug-resistant (MDR) and extensively drug-resistant (XDR) pathogens has made effective treatment more difficult, underscoring the need for localized resistance data to guide therapy. This study aimed to investigate the distribution and AMR profiles of pathogens isolated from sputum and pus samples, with particular emphasis on MDR and XDR strains. Methods: A retrospective study was conducted from December 2024 to April 2025, analyzing 615 sputum and 45 pus samples from patients at Madan Bhandari Hospital and Trauma Center in Eastern Nepal. Bacterial identification and antimicrobial susceptibility testing were performed according to validated government-approved guidelines (AMR Bacteriology Standard Operating Procedure, 2024). MDR and XDR strains were classified based on the criteria provided by the European Centre for Disease Prevention and Control (ECDC) and the Centers for Disease Control and Prevention (CDC). Results: A total of 66 sputum (10.73%) and 17 pus (37.78%) samples showed positive bacterial growth. Conclusion: The notable prevalence of MDR and XDR pathogens, along with antibiotic resistance, underscores the need for updated treatment guidelines. Meropenem remains effective for severe infections, while gentamicin and doxycycline are suitable for targeted therapies. Strengthening antimicrobial stewardship, diagnostics, and infection control is crucial to address AMR in Eastern Nepal.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.